© 2022 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Erin Crane, MD, reviews the case of a 63-year-old woman with recurrent ovarian cancer and discusses treatment options, the Phase 3 NOVA trial, and the future of ovarian cancer treatment.
April 14th 2021
Erin Crane, MD, provides an overview of a 63-year-old female patient diagnosed with recurrent ovarian cancer, discussing the initial presentation, clinical work-up, treatment, and her initial impression of the case.
An expert in ovarian cancer discusses the role of molecular testing in ovarian cancer and the benefits of incorporating systemic frontline therapy into treatment plans.
Erin Crane, MD, reviews second- and third-line treatment options and the impact of platinum sensitivity on treatment selection.
Erin Crane, MD, provides an overview of the Phase 3 NOVA trial.
Erin Crane, MD, discusses the role of PARP inhibitors in the treatment of ovarian cancer.
An expert in ovarian cancer considers the future of ovarian cancer treatment, the use of PARP inhibitors and overcoming PARP resistance, and the emerging treatments options.